{
    "id": 517,
    "fullName": "HRAS wild-type",
    "impact": "none",
    "proteinEffect": "no effect",
    "geneVariantDescriptions": [
        {
            "description": "Wild-type HRAS indicates that no mutation has been detected within the HRAS gene.",
            "references": [
                {
                    "id": 275,
                    "pubMedId": null,
                    "title": "External Reference Not Available (N/A)",
                    "url": "https://ckb.jax.org/about/glossaryOfTerms"
                }
            ]
        }
    ],
    "type": "non-specific",
    "gene": {
        "id": 3265,
        "geneSymbol": "HRAS",
        "terms": [
            "HRAS",
            "C-BAS/HAS",
            "C-H-RAS",
            "C-HA-RAS1",
            "CTLO",
            "H-RASIDX",
            "HAMSV",
            "HRAS1",
            "p21ras",
            "RASH1"
        ]
    },
    "variant": "wild-type",
    "createDate": "05/13/2014",
    "updateDate": "10/01/2018",
    "referenceTranscriptCoordinates": null,
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 1299,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the farnesyltransferase inhibitor FTI-277 sensitized Hras transformed rat fibroblasts to radiation therapy (PMID: 8620483).",
            "molecularProfile": {
                "id": 575,
                "profileName": "HRAS wild-type"
            },
            "therapy": {
                "id": 1683,
                "therapyName": "FTI-277",
                "synonyms": null
            },
            "indication": {
                "id": 162,
                "name": "cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 1008,
                    "pubMedId": 8620483,
                    "title": "The farnesyltransferase inhibitor FTI-277 radiosensitizes H-ras-transformed rat embryo fibroblasts.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/8620483"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5626,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, E6201 inhibited proliferation of several melanoma cell lines in culture and hypersensitivity was associated with wild-type HRAS (PMID: 23039341).",
            "molecularProfile": {
                "id": 575,
                "profileName": "HRAS wild-type"
            },
            "therapy": {
                "id": 1011,
                "therapyName": "E6201",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 1840,
                    "pubMedId": 23039341,
                    "title": "Sensitivity to the MEK inhibitor E6201 in melanoma cells is associated with mutant BRAF and wildtype PTEN status.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23039341"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 575,
            "profileName": "HRAS wild-type",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        
    ]
}